Browse > Article

Establishment of Dissolution Specifications for Octylonium Bromide Tablets and Pinaverium Bromide Tablets  

Lee, Ryun-Kyung (Hazardous Substances Analysis Division, Daegu Regional Food & Drug Administration)
Lee, Yoon-Ae (Hazardous Substances Analysis Division, Daegu Regional Food & Drug Administration)
Shim, Jee-Youn (Hazardous Substances Analysis Division, Daegu Regional Food & Drug Administration)
Kim, Min-A (Hazardous Substances Analysis Division, Daegu Regional Food & Drug Administration)
Sohn, Kyung-Hee (National Institute of Food and Drug Safety Evaluation, Osong Health Technology Administration Complex)
Park, Hye-Rim (Korea Food & Drug Administration, Osong Health Technology Administration Complex)
Kim, Hee-Sung (Korea Food & Drug Administration, Osong Health Technology Administration Complex)
Song, Young-Mi (Korea Food & Drug Administration, Osong Health Technology Administration Complex)
Lee, Su-Jung (Korea Food & Drug Administration, Osong Health Technology Administration Complex)
Sah, Hong-Kee (College of Pharmacy, Ewha Womans University)
Choi, Hoo-Kyun (College of Pharmacy, Chson University)
Kim, Young-Ok (Korea Food & Drug Administration, Osong Health Technology Administration Complex)
Kim, Dong-Sup (National Institute of Food and Drug Safety Evaluation, Osong Health Technology Administration Complex)
Cho, Tae-Yong (Hazardous Substances Analysis Division, Daegu Regional Food & Drug Administration)
Publication Information
YAKHAK HOEJI / v.55, no.5, 2011 , pp. 419-425 More about this Journal
Abstract
To secure the good quality of pharmaceutical products, dissolution specifications for Octylonium bromide tablets and Pinaverium bromide tablets are needed to be established, which are enrolled in KPC (Korea Pharmaceutical Codex) with having no appropriate specifications. For establishing dissolution specifications, a number of experiments based on the "Guideline of Dissolution Testing for Solide Oral Dosage Forms" were performed. The results of this study will be used for revising KPC and it is expected to contribute to the incessant production of quality ensured drugs.
Keywords
dissolution test; octylonium bromide; pinaverium bromide;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Scarpignato, C. and Pelosini, I. : Management of irritable bowel syndrome, novel approaches to the pharmacology of gut motility. Can. J. Gastroenterol. 13, 50A (1999)   DOI
2 Dai, Y., Liu, J. X., Li, J. X. and Xu, Y. F. : Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats. World J. Gastroenterol. 9, 557 (2003).   DOI
3 식품의약품안전청 용역연구개발사업 : 브롬화피나베리움의 생체이 용률시험 및 생물학적동등성시험 표준지침 작성, 한상범 등 (2004).
4 대한약전 9개정 : 경구용의약품의 용출규격 설정 지침 (2007).
5 식품의약품안전청 고시 : 의약품동등성시험관리규정 (2005).
6 대한약전 9개정 : 의약품등 분석법의 밸리데이션에 대한 지침 (2007).
7 식품의약품안전청 연구개발사업 : 고시수재 의약품의 용출규격 설정에 관한 연구, 김영옥 등 (2009).
8 식품의약품안전청 : 대한약전 의약품등 기준 제 3개정 (2007).
9 de Weerdt, G. A., Beke, R. P., Verdievel, H. G., Barbier, F., Jonckheere, J. A. and de Leenheer, A. P.: Quantitative gas chromatographic mass spectrometric determination of pinaverium-bromide in human serum. Biomed. Mass Spectrum. 10, 162 (1983).   DOI   ScienceOn
10 식품의약품안전청 용역연구개발사업 : 의약품 동등성 재평가 대상 성분의 생동성 평가방법에 관한 연구(브롬화옥틸로늄), 강원구 등 (2006).
11 Lu, C. L., Chen, C. Y., Chang, F. Y., Chang, S. S., Kang, L. J., Lu, R. H. and Lee, S. D. : Effect of a calcium channel blocker and antispasmodic in diarrhea-predominant irritable bowel syndrome. J. Gastrsenterol. Hepatol. 15, 925 (2000).   DOI   ScienceOn
12 Bouchoucha, M., Faye, A., Devroede, G. and Arsac, M. : Effect of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients. Biomed. Pharmacother. 54, 381 (2000).   DOI   ScienceOn